Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voyage: DT120 in Generalized Anxiety Disorder
NCT06741228Phase 3Active, not recruiting
- Sponsor
- Definium Therapeutics
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Arm 1 - Placebo with Arm 2 - 100µg DT120 (2 arms). Primary endpoint: Hamilton Anxiety Rating Scale at 12 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
lysergic acid diethylamide D-tartrate
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06741228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741228.